“Prolyl-leucyl-glycinamide shares some effects with oxytocin but decreases oxytocin levels”. Physiology & Behavior83 (3): 475-81. (December 2004). doi:10.1016/j.physbeh.2004.08.034. PMID15581670.
“Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide”. European Journal of Pharmacology53 (2): 119-25. (January 1979). doi:10.1016/0014-2999(79)90156-0. PMID32058.
“Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence”. Life Sciences34 (26): 2559-66. (June 1984). doi:10.1016/0024-3205(84)90041-9. PMID6146083.
“Antagonism of morphine analgesia by prolyl-leucyl-glycinamide (MIF-1) in humans”. Pharmacology Biochemistry and Behavior21 (6): 975-8. (December 1984). doi:10.1016/S0091-3057(84)80083-0. PMID6151672.
“Antiopioid properties of the TYR-MIF-1 family”. Methods and Findings in Experimental and Clinical Pharmacology26 (9): 673-7. (November 2004). doi:10.1358/mf.2004.26.9.872564. PMID15632952.
“Effects of L-prolyl-L-leucyl-glycine amide (MIF-I) on dopaminergic neurons”. Pharmacology Biochemistry and Behavior5 (Suppl 1): 125-7. (1976). doi:10.1016/0091-3057(76)90340-3. PMID13412.
“MIF-1: effects on norepinephrine, dopamine and serotonin metabolism in certain discrete brain regions”. Pharmacology Biochemistry and Behavior16 (2): 229-33. (February 1982). doi:10.1016/0091-3057(82)90153-8. PMID6122214.
“Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG)”. Peptides6 (2): 179-83. (1985). doi:10.1016/0196-9781(85)90036-1. PMID2863809.
“Inhibition by L-prolyl-L-leucyl-glycinamide (PLG) of alpha-melanocyte stimulating hormone release from hypothalamic slices”. Peptides3 (6): 885-9. (1982). doi:10.1016/0196-9781(82)90055-9. PMID6132363.
“Inhibition by MIF-I of alpha-MSH induced increase of intraocular pressure and miosis in rabbits”. Neuropeptides12 (4): 213-7. (1988). doi:10.1016/0143-4179(88)90057-1. PMID2907121.
“The effect of the blockade of alpha-melanocyte-stimulating hormone on LH release in the rat”. The Journal of Endocrinology137 (2): 197-202. (May 1993). doi:10.1677/joe.0.1370197. PMID8100849.
Sandyk R (May 1990). “MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders”. The International Journal of Neuroscience52 (1-2): 59-65. doi:10.3109/00207459008994244. PMID1979968.
“MIF-1 is active in a chronic stress animal model of depression”. Pharmacology Biochemistry and Behavior32 (3): 737-42. (March 1989). doi:10.1016/0091-3057(89)90027-0. PMID2568001.
“MIF-1 potentiates the action of tricyclic antidepressants in an animal model of depression”. Peptides12 (5): 915-8. (1991). doi:10.1016/0196-9781(91)90037-p. PMID1686934.
“Improvement in major depression after low subcutaneous doses of MIF-1”. Journal of Affective Disorders31 (4): 227-33. (August 1994). doi:10.1016/0165-0327(94)90098-1. PMID7989637.
“Increased acquisition of a complex appetitive task after MSH and MIF”. Pharmacology Biochemistry and Behavior3 (5): 901-4. (1975). doi:10.1016/0091-3057(75)90124-0. PMID1801.
“Memory enhancement induced in chicks by L-prolyl-L-leucyl-glycinamide”. Pharmacology Biochemistry and Behavior17 (5): 893-6. (November 1982). doi:10.1016/0091-3057(82)90467-1. PMID6129646.
“Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets”. Movement Disorders22 (5): 715-9. (April 2007). doi:10.1002/mds.21256. PMID17373723.
“MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats”. Peptides28 (10): 2009-15. (October 2007). doi:10.1016/j.peptides.2007.07.026. PMID17766011.
“Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine”. Peptides15 (1): 23-9. (January 1994). doi:10.1016/0196-9781(94)90165-1. PMID7912427.
“Melanocyte-stimulating hormone release-inhibiting factor-1 (MIF-1) can be formed from Tyr-MIF-1 in brain mitochondria but not in brain homogenate”. Journal of Neurochemistry64 (4): 1855-9. (April 1995). doi:10.1046/j.1471-4159.1995.64041855.x. PMID7891114.
“Prolyl-leucyl-glycinamide shares some effects with oxytocin but decreases oxytocin levels”. Physiology & Behavior83 (3): 475-81. (December 2004). doi:10.1016/j.physbeh.2004.08.034. PMID15581670.
“Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide”. European Journal of Pharmacology53 (2): 119-25. (January 1979). doi:10.1016/0014-2999(79)90156-0. PMID32058.
“Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence”. Life Sciences34 (26): 2559-66. (June 1984). doi:10.1016/0024-3205(84)90041-9. PMID6146083.
“Antagonism of morphine analgesia by prolyl-leucyl-glycinamide (MIF-1) in humans”. Pharmacology Biochemistry and Behavior21 (6): 975-8. (December 1984). doi:10.1016/S0091-3057(84)80083-0. PMID6151672.
“Antiopioid properties of the TYR-MIF-1 family”. Methods and Findings in Experimental and Clinical Pharmacology26 (9): 673-7. (November 2004). doi:10.1358/mf.2004.26.9.872564. PMID15632952.
“Effects of L-prolyl-L-leucyl-glycine amide (MIF-I) on dopaminergic neurons”. Pharmacology Biochemistry and Behavior5 (Suppl 1): 125-7. (1976). doi:10.1016/0091-3057(76)90340-3. PMID13412.
“MIF-1: effects on norepinephrine, dopamine and serotonin metabolism in certain discrete brain regions”. Pharmacology Biochemistry and Behavior16 (2): 229-33. (February 1982). doi:10.1016/0091-3057(82)90153-8. PMID6122214.
“Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG)”. Peptides6 (2): 179-83. (1985). doi:10.1016/0196-9781(85)90036-1. PMID2863809.
“Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease”. Advances in Neurology45: 587-90. (1987). PMID2881450.
“Inhibition by L-prolyl-L-leucyl-glycinamide (PLG) of alpha-melanocyte stimulating hormone release from hypothalamic slices”. Peptides3 (6): 885-9. (1982). doi:10.1016/0196-9781(82)90055-9. PMID6132363.
“Inhibition by MIF-I of alpha-MSH induced increase of intraocular pressure and miosis in rabbits”. Neuropeptides12 (4): 213-7. (1988). doi:10.1016/0143-4179(88)90057-1. PMID2907121.
“The effect of the blockade of alpha-melanocyte-stimulating hormone on LH release in the rat”. The Journal of Endocrinology137 (2): 197-202. (May 1993). doi:10.1677/joe.0.1370197. PMID8100849.
Sandyk R (May 1990). “MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders”. The International Journal of Neuroscience52 (1-2): 59-65. doi:10.3109/00207459008994244. PMID1979968.
“MIF-1 is active in a chronic stress animal model of depression”. Pharmacology Biochemistry and Behavior32 (3): 737-42. (March 1989). doi:10.1016/0091-3057(89)90027-0. PMID2568001.
“MIF-1 potentiates the action of tricyclic antidepressants in an animal model of depression”. Peptides12 (5): 915-8. (1991). doi:10.1016/0196-9781(91)90037-p. PMID1686934.
“Improvement in major depression after low subcutaneous doses of MIF-1”. Journal of Affective Disorders31 (4): 227-33. (August 1994). doi:10.1016/0165-0327(94)90098-1. PMID7989637.
“Increased acquisition of a complex appetitive task after MSH and MIF”. Pharmacology Biochemistry and Behavior3 (5): 901-4. (1975). doi:10.1016/0091-3057(75)90124-0. PMID1801.
“Memory enhancement induced in chicks by L-prolyl-L-leucyl-glycinamide”. Pharmacology Biochemistry and Behavior17 (5): 893-6. (November 1982). doi:10.1016/0091-3057(82)90467-1. PMID6129646.
“Neurological effects of MIF-1, MSH, and opiate peptides in clinical studies”. International Journal of Neurology14 (2-4): 205-9. (1980). PMID6152908.
“Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets”. Movement Disorders22 (5): 715-9. (April 2007). doi:10.1002/mds.21256. PMID17373723.
“MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats”. Peptides28 (10): 2009-15. (October 2007). doi:10.1016/j.peptides.2007.07.026. PMID17766011.
“Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine”. Peptides15 (1): 23-9. (January 1994). doi:10.1016/0196-9781(94)90165-1. PMID7912427.
“Melanocyte-stimulating hormone release-inhibiting factor-1 (MIF-1) can be formed from Tyr-MIF-1 in brain mitochondria but not in brain homogenate”. Journal of Neurochemistry64 (4): 1855-9. (April 1995). doi:10.1046/j.1471-4159.1995.64041855.x. PMID7891114.